相关实验视频

Updated: Jan 17, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

miR-199a-5p/GPR89A轴通过谷氨酸代谢重编程调节肝细胞癌中索拉芬尼抗性的作用

Yao Li¹, Yi Cai², Guangliang Duan³

¹Anhui Provincial Key Laboratory of Immunology in Chronic Diseases, Anhui Provincial Key Laboratory of Infection and Immunology, and Department of Laboratory Medicine, Bengbu Medical University, Anhui, China.

Science progress

|September 23, 2025

概括

通过改变谷氨酸代谢,GPR89A的过度表达驱动了肝细胞癌 (HCC) 中的索拉芬尼抗性. 通过miR-199a-5p抑制GPR89A为克服HCC患者药物耐药性的潜在治疗策略提供了机会.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

索拉菲尼布是肝细胞癌 (HCC) 的关键向治疗方法.
对索拉费尼布的获得药物耐药性显著限制了其在HCC治疗中的临床有效性.
GPR89A在抗索拉尼布的HCC中过度表达,但其作用尚不清楚.

研究的目的:

调查GPR89A在HCC中索拉芬尼布耐药性的发展中的生物学作用.
阐明GPR89A介导的索拉费尼布耐药性的基础分子机制.
探索针对GPR89A的潜力,以克服HCC.中的索拉芬尼布耐药性.

主要方法:

产生抗索拉芬尼布的HCC细胞系,并通过qRT-PCR和西欧斑块分析GPR89A的表达.
在抑制GPR89A时评估细胞增殖和殖民地形成.
路西法雷斯记者测定证实了miR-199a-5p针对GPR89A的目标.
在临床HCC样本中测量谷氨酸水平和与GPR89A,miR-199a-5p和mGluR1表达的相关性分析.

主要成果:

在抗索拉芬尼布的HCC细胞系和患者瘤中,GPR89A显著过度表达,与耐药性正相关.
抗索拉费尼布的HCC组织显示GPR89A和mGluR1增加,miR-199a-5p表达减少.
miR-199a-5p直接准GPR89A,降低mGluR1的调节,影响谷氨酸水平,从而影响增殖.

结论:

过度表达GPR89A是HCC中获得索拉芬尼布耐药性的关键驱动因素.
一个涉及GPR89A,miR-199a-5p和谷氨酸代谢的新型调节轴有助于索拉芬尼布耐药性.
准GPR89A/miR-199a-5p/mGluR1通路可能是对抗性HCC的治疗策略.

关键词:

在GPR89A中使用.谷氨酸酸盐的使用方法肝细胞癌是肝细胞癌.在 miR-199a-5p 中.索拉费尼布耐药性索拉费尼布耐药性

更多相关视频

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...